{"filings":[{"id":40642,"accession_number":"0001104659-26-059409","cik":724445,"company_name":"BURZYNSKI RESEARCH INSTITUTE INC","ticker":"BZYR","form_type":"8-K","filed_at":"2026-05-12T20:15:55+00:00","items":["8.01"],"status":"ready","headline":"Burzynski Research expects to miss 10-K filing; majority owner stops funding SEC costs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dr. Stanislaw Burzynski, beneficial owner of majority of BZYR common stock, will not fund SEC reporting costs due to limited resources.","Company expects it will be unable to file its FY 2026 Form 10-K due May 29, 2026, and subsequent periodic reports.","Continued delinquency may lead to SEC suspension of trading under Section 12(k) or revocation of registration under Section 12(j).","If registration is suspended/revoked, broker-dealers may be restricted from quoting BZYR, severely reducing trading liquidity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1708830.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":98516,"accession_number":"0001104659-26-047711","cik":724445,"company_name":"BURZYNSKI RESEARCH INSTITUTE INC","ticker":"BZYR","form_type":"8-K","filed_at":"2026-04-23T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CFO Patryk P. Goscianski resigns; CEO Stanislaw R. Burzynski appointed CFO and Secretary","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Patryk P. Goscianski resigned as CFO and Secretary on April 16, effective April 17, 2026; no disagreement cited.","Board appointed Dr. Stanislaw R. Burzynski, age 83, as CFO and Secretary effective April 17, with no additional compensation.","Dr. Burzynski already serves as President, Chairman, and principal executive officer; now also principal financial and accounting officer.","Dr. Burzynski is the controlling stockholder and party to related-party agreements; the other board members are his sons."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1708830.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":146996,"accession_number":"0001410578-25-002050","cik":724445,"company_name":"BURZYNSKI RESEARCH INSTITUTE INC","ticker":"BZYR","form_type":"8-K/A","filed_at":"2025-09-11T23:59:59+00:00","items":["4.01"],"status":"ready","headline":"BZYR appoints M&K CPA's PLLC as new independent auditor following PKF resignation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PKF resigned as auditor on July 21, 2025, due to acquisition by another firm; no disagreements or reportable events.","Board approved M&K CPA's PLLC as independent auditor on September 9, 2025, for fiscal year ending Feb 28, 2026.","No prior consultations with M&K regarding accounting principles, audit opinions, or disagreements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1708830.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":146997,"accession_number":"0001104659-25-070376","cik":724445,"company_name":"BURZYNSKI RESEARCH INSTITUTE INC","ticker":"BZYR","form_type":"8-K","filed_at":"2025-07-24T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Burzynski Research Institute auditor PKF resigns after acquisition; no disagreements","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PKF resigned as independent registered public accounting firm effective July 21, 2025, citing its acquisition by another firm.","No disagreements or reportable events occurred between the Company and PKF in the two most recent fiscal years or subsequent interim period.","Company plans to engage a new independent auditor and will file an 8-K/A upon appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1708830.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":307545,"accession_number":"0001104659-23-063151","cik":724445,"company_name":"BURZYNSKI RESEARCH INSTITUTE INC","ticker":"BZYR","form_type":"8-K","filed_at":"2023-05-22T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"BZYR licenses antineoplaston patents from CEO; research funding secured through Feb 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["License from Dr. Burzynski for exclusive rights to four US patents and pending applications for antineoplastons in US/Canada.","Research Funding Agreement: Dr. Burzynski funds all basic research and FDA-related trial costs; term to Feb 2024, auto-renewable.","Amended Royalty and Research Funding Agreements limited to US/Canada scope.","License can terminate if Burzynski removed as officer/director or if another party equals his voting power."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1708830.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":307544,"accession_number":"0001104659-23-042811","cik":724445,"company_name":"BURZYNSKI RESEARCH INSTITUTE INC","ticker":"BZYR","form_type":"8-K","filed_at":"2023-04-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Carlton Hazlewood resigns from Burzynski Research Institute board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Carlton Hazlewood resigned from the Board of Directors effective April 6, 2023.","Resignation is for personal reasons and not due to any disagreement with the Company.","No replacement or other board changes announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1708830.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":417038,"accession_number":"0001104659-21-123645","cik":724445,"company_name":"BURZYNSKI RESEARCH INSTITUTE INC","ticker":"BZYR","form_type":"8-K","filed_at":"2021-10-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Burzynski Research appoints Monika Szopa-Paszkowiak to board to fill vacancy after Barbara Burzynski's death","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Monika Szopa-Paszkowiak appointed to board on October 6, 2021, filling vacancy from Dr. Barbara Burzynski's passing.","She is step-daughter of President and Chairman Stanislaw R. Burzynski.","Her background includes pharmaceutical manufacturing, patient care, and HR at Burzynski Clinic; currently a real estate agent.","She holds a bachelor's degree from Houston Baptist University.","Appointment is effective immediately until successor is appointed or earlier resignation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1708830.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}